Эозинофильное воспаление при хронической обструктивной болезни легких
________________________________________________
Avdeev S.N., Trushenko N.V., Merzhoeva Z.M., et al. Eosinophilic inflammation in chronic obstructive pulmonary disease Therapeutic Archive. 2019; 91 (10): 144–152. DOI: 10.26442/00403660.2019.10.000426
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Ключевые слова: ХОБЛ, фенотип, эозинфилия, эозинофильное воспаление, ингаляционные глюкокортикостероиды.
________________________________________________
Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease that combines various clinical manifestations and pathophysiological mechanisms. It underlies the separation of patients with COPD by phenotypes, endotypes and a personalized therapy of this disease. The implementation of this approach is possible only with the use of appropriate biomarkers. One of the most important biomarkers of COPD is eosinophilia of blood and/or sputum, which is considered as a predictor of frequent exacerbations and the effectiveness of inhaled glucocorticosteroids in patients with COPD. The literature discusses the impact of eosinophilic inflammation on the prognosis, clinical and functional parameters in COPD, and the role of the targeted therapy in the treatment of eosinophilic COPD.
Keywords: COPD, phenotype, eosinophilia, eosinophilic inflammation, inhaled glucocorticosteroids.
2. Fragoso E, André S, Boleo-Tomé JP, Areias V, Munhá J, Cardoso J. Understanding COPD: A vision on phenotypes, comorbidities and treatment approach. GI COPD – Interest Group on Chronic Obstructive Pulmonary Disease. Rev Port Pneumol. 2016 Mar-Apr;22(2):101-11. doi: 10.1016/j.rppnen.2015.12.001. Epub 2016 Jan 27. Review.
3. Saetta M, Di Stefano A, Maestrelli P, Turato G, Ruggieri MP, Roggeri A, Calcagni P, Mapp CE, Ciaccia A, Fabbri LM. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med. 1994;150:1646-52. doi: 10.1164/ajrccm.150.6.7952628
4. Saetta M, Di Stefano A, Maestrelli P, Turato G, Mapp CE, Pieno M, Zanguochi G, Del Prete G, Fabbri LM. Airway eosinophilia and expression of interleukin-5 protein in asthma and in exacerbations of chronic bronchitis. Clin Exp Allergy. 1996;26:766-74. doi: 10.1007/978-3-0348-7939-2_2
5. Pizzichini E, Pizzichini MM, Gibson P, Parameswaran K, Gleich GJ, Berman L, Dolovich J, Hargreave FE. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med. 1998;158(5 Pt 1):1511-7. doi: 10.1164/ajrccm.158.5.9804028
6. Landis S, Suruki R, Bonar K, Hilton E, Compton C. Demographic and Clinical Characteristics of COPD Patients at Different Blood eosinophil levels in the UK Clinical Practice Research Datalink (CPRD). Am J Respir Crit Care Med. 2016;193:A6329. DOI: 10.1080/15412555.2018.1441275
7. Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomized controlled trials. Lancet Respir Med. 2015;3(6):435-42. doi: 10.1016/S2213-2600(15)00106-X. Epub 2015 Apr 12.
8. Singh D, Kolsum U, Brightling CE, Locantore N, Agusti A, Tal-Singer R. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J. 2014 Dec;44(6):1697-700. doi: 10.1183/09031936.00162414. Epub 2014 Oct 16.
9. George L, Brightling CE Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease. Ther Adv Chronic Dis. 2016;7(1):34-51. doi: 10.1177/2040622315609251
10. Joo MJ, Au DH, Fitzgibbon ML, Lee TA. Inhaled corticosteroids and risk of pneumonia in newly diagnosed COPD. Respir Med. 2010 Feb;104(2):246-52. doi: 10.1016/j.rmed.2009.10.002. Epub 2009 Oct 30.
11. Morjaria JB, Rigby A, Morice AH. Inhaled Corticosteroid use and the Risk of Pneumonia and COPD Exacerbations in the UPLIFT Study. Lung. 2017 Jun;195(3):281-8. doi: 10.1007/s00408-017-9990-8. Epub 2017 Mar 3.
12. Yang M, Chen H, Zhang Y, Du Y, Xu Y, Jiang P, Xu Z. Long-term use of inhaled corticosteroids and risk of upper respiratory tract infection in chronic obstructive pulmonary disease: a meta-analysis. Inhal Toxicol. 2017 Apr;29(5):219-26. doi: 10.1080/08958378.2017.1346006. Epub 2017 Jul 17.
13. Di Santostefano RL, Hinds D, Le HV, Barnes NC. Relationship between blood eosinophils and clinical characteristics in a cross-sectional study of a US population-based COPD cohort. Respir Med. 2016 Mar;112:88-96. doi: 10.1016/j.rmed.2016.01.013. Epub 2016 Jan 22.
14. Kolsum U, Damera G, Pham TH, Southworth T, Mason S, Karur P, Newbold P, Singh D. Pulmonary inflammation in patients with chronic obstructive pulmonary disease with higher blood eosinophil counts. J Allergy Clin Immunol. 2017 Oct;140(4):1181-4.e7. doi: 10.1016/j.jaci. 2017.04.027. Epub 2017 May.
15. Hasegawa K, Camargo CA. 2016 Prevalence of blood eosinophilia in hospitalized patients with acute exacerbation of COPD. Respirology. 2016;21:761-4. doi: 10.1111/resp.12724
16. Bafadhel M, Saha S, Siva R, McCormick M, Monteiro W, Rugman P, Dodson P, Pavord ID, Newbold P, Brightling CE. Sputum IL-5 concentration is associated with a sputum eosinophilia and attenuated by corticosteroid therapy in COPD. Respiration. 2009;78:256-62. doi: 10.1159/000221902
17. Ying S, O'Connor B, Ratoff J, Meng Q, Fang C, Cousins D, Zhang G, Gu S, Gao Z, Shamji B, Edwards MJ, Lee TH, Corrigan CJ. Expression and cellular provenance of thymic stromal lymphopoietin and chemokines in patients with severe asthma and chronic obstructive pulmonary disease. J Immunol. 2008;181:2790-8. doi: 10.4049/jimmunol.181.4.2790
18. Saha S, Doe C, Mistry V, Siddiqui S, Parker D, Sleeman M, Cohen ES, Brightling CE. Granulocyte-macrophage colony-stimulating factor expression in induced sputum and bronchial mucosa in asthma and COPD. Thorax. 2009 Aug;64(8):671-6. doi: 10.1136/thx.2008.108290. Epub 2009 Feb 12.
19. Tworek D, Antczak A. Eosinophilic COPD – a distinct phenotype of the disease. Adv Respir Med. 2017;85(5):271-6. doi: 10.5603/ARM.a2017.0045
20. D'Armiento JM, Scharf SM, Roth MD, Connett JE, Ghio A, et al. Eosinophil and T cell markers predict functional decline in COPD patients. Respir Res. 2009 Nov 19;10:113. doi: 10.1186/1465-9921-10-113
21. Ponath PD, Qin S, Ringler DJ, Clark-Lewis I, et al. Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. J Clin Invest. 1996 Feb 1;97(3):604-12. doi: 10.1172/JCI118456
22. Brusselle G, Pavord ID, Landis S, Pascoe S, Lettis S, Morjaria N, Barnes N, Hilton E. Blood eosinophil levels as a biomarker in COPD. Respir Med. 2017. doi: 10.1016/ j.rmed.2018.03.016
23. Barnes PJ. Inflammatory Endotypes in COPD. Allergy. 2019 Mar 4. doi: 10.1111/all.13760
24. Christenson SA, Steiling K, van den Berge M, Hijazi K, Hiemstra PS, Postma DS, Lenburg ME, Spira A, Woodruff PG. Asthma-COPD overlap. Clinical relevance of genomic signatures of type 2 inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;191(7):758-66. doi: 10.1164/rccm.201408-1458OC
25. Brightling CE, Bleecker ER, Panettieri RA Jr, Bafadhel M, She D, Ward CK, Xu X, Birrell C, van der Merwe R. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med. 2014 Nov;2(11):891-901. doi: 10.1016/S2213-2600(14)70187-0. Epub 2014 Sep 7.
26. Eltboli O, Bafadhel M, Hollins F, Wright A, Hargadon B, Kulkarni N, Brightling C. COPD exacerbation severity and frequency is associated with impaired macrophage efferocytosis of eosinophils. BMC Pulm Med. 2014 Jul 9;14:112. doi: 10.1186/1471-2466-14-112
27. Akiyama M, Yasuoka H, Yoshimoto K, Takeuchi T. CC-chemokine ligand 18 is a useful biomarker associated with disease activity in IgG4-related disease. Ann Rheum Dis. 2018 Sep;77(9):1386-7. doi: 10.1136/annrheumdis-2017-212110. Epub 2017 Oct 13.
28. Laucho-Contreras ME, Polverino F, Tesfaigzi Y, Pilon A, Celli BR, Owen CA. Club Cell Protein 16 (CC16) Augmentation: A Potential Disease-modifying Approach for Chronic Obstructive Pulmonary Disease (COPD). Expert Opin Ther Targets. 2016 Jul;20(7):869-83. doi: 10.1517/14728222.2016.1139084. Epub 2016 Feb 11.
29. Tashkin DP, Wechsler ME. Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2018 Jan 17;13:335-49. doi: 10.2147/COPD.S152291. eCollection 2018.
30. Bafadhel M, McKenna S, Terry S, Mistry V, et al. Acute exacerbations of chronic obstructive pulmonary disease: Identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184:662-71. doi: 10.1164/rccm.201104-0597OC
31. McDonald VM, Higgins I, Wood LG, Gibson PG. Multidimensional assessment and tailored interventions for COPD: respiratory utopia or common sense? Thorax. 2013;68(7):691-4. doi: 10.1136/thoraxjnl-2012-202646. Epub 2013 Mar 16.
32. Leigh R, Pizzichini MM, Morris MM, Maltais F, Hargreave FE, Pizzichini E. Stable COPD: predicting benefits from high-dose inhaled corticosteroid treatment. Eur Respir J. 2006;27(5):964-71. doi: 10.1183/09031936.06.00072105
33. Cheng SL, Lin CH. Effectiveness using higher inhaled corticosteroid dosage in patients with COPD by different blood eosinophilic counts. Int J Chron Obstruct Pulmon Dis. 2016 Sep 21;11:2341-8. eCollection 2016. doi: 10.2147/COPD.S115132
34. Baines KJ, Pavord ID, Gibson PG. The role of biomarkers in the management of airways disease. Int J Tuberc Lung Dis. 2014 Nov;18(11):1264-8. doi: 10.5588/ijtld.14.0226
35. Simpson JL, Bafadhel M. Alternatives to induced sputum for identifying inflammatory subtypes of asthma. Respirology. 2017 May;22(4):624-5. doi: 10.1111/resp.13036. Epub 2017 Mar 29. PMID: 28370689
36. Hastie AT, Alexis NE, Doerschuk C, Hansel NN, Christenson S, Putcha N, et al. Blood eosinophils poorly correlate with sputum eosinophils, and have few associations with spirometry, clinical and quantitated computed tomography measures compared to sputum eosinophils in the SPIROMICS cohort. Am J Respir Crit Care Med. 2016;193:A6168.
37. Kolsum U, Ravi A, Hitchen P, Maddi S, Southworth T, Singh D. Clinical characteristics of eosinophilic COPD versus COPD patients with a history of asthma. Respir Res. 2017;18:73. Pub. online 2017 Apr 26. doi: 10.1186/s12931-017-0559-0
38. Negewo NA, McDonald VM, Baines KJ, Wark PA, Simpson JL, Jones PW, Gibson PG. Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD. Int J Chron Obstruct Pulmon Dis. 2016 Jul 1;11:1495-504. doi: 10.2147/COPD.S100338. eCollection 2016.
39. Turato G, Semenzato U, Bazzan E, Biondini D, Tinè M, Torrecilla N, Forner M, Marin JM, Cosio MG, Saetta M. Blood Eosinophilia Neither Reflects Tissue Eosinophils nor Worsens Clinical Outcomes in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2018 May 1;197(9):1216-9. doi: 10.1164/rccm.201708-1684LE
40. Yilmaz I, Turk M. What Should Be the Cutoff Value of Blood Eosinophilia as a Predictor of Inhaled Corticosteroid Responsiveness in Patients with Chronic Obstructive Pulmonary Disease? Am J Respir Crit Care Med. 2017 Nov 1;196(9):1229-30. doi: 10.1164/rccm.201705-0892LE
41. Wedzicha JA. Eosinophils as biomarkers of chronic obstructive pulmonary disease exacerbation risk: maybe just for some? Am J Respir Crit Care Med. 2016;193:937-8. doi: 10.1164/rccm.201601-0015ED
42. Shin SH, Park HY, Kang D, Cho J, Kwon SO, Park JH, Lee JS, Oh YM, Sin DD, Kim WJ, Lee SD and KOLD Study Group. Serial blood eosinophils and clinical outcome in patients with chronic obstructive pulmonary disease. Respir Res. 2018 Jul 13;19(1):134. doi: 10.1186/s12931-018-0840-x
43. Calverley PMA, Tetzlaff K, Vogelmeier C, Fabbri LM, Magnussen H, Wouters EFM, Mezzanotte W, Disse B, Finnigan H, Asijee G, Hallmann C, Watz H. Eosinophilia, frequent exacerbations, and steroid response in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017 Nov 1;196(9):1219-21. doi: 10.1164/rccm.201612-2525LE
44. Casanova C, Celli BR, de-Torres JP, Martínez-Gonzalez C, et al. Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD. Eur Respir J. 2017;50(5). pii: 1701162. doi: 10.1183/13993003.01162-2017
45. Szefler SJ, Wenzel S, Brown R, Erzurum SC, et al. Asthma outcomes: biomarkers. J Allergy Clin Immunol. 2012 Mar;129(3 Suppl):S9-23. doi: 10.1016/j.jaci.2011.12.979
46. Oshagbemi OA, Burden AM, Braeken DCW, Henskens Y, et al. Stability of blood eosinophils in patients with chronic obstructive pulmonary disease and in control subjects, and the impact of sex, age, smoking, and baseline counts. Am J Respir Crit Care Med. 2017;195(10):1402-4. doi: 10.1164/rccm.201701-0009LE
47. Sennels HP, Jørgensen HL, Hansen AL, Goetze JP, Fahrenkrug J. Diurnal variation of hematology parameters in healthy young males: the Bispebjerg study of diurnal variations. Scand J Clin Lab Invest. 2011;71(7):532-41. doi: 10.3109/00365513.2011.602422
48. Shekelle RB, Shryock AM, Paul O, Lepper M, Stamler J, Liu S, et al. Diet, serum cholesterol, and death from coronary heart disease. The Western Electric study. N Engl J Med. 1981;304(2):65-70. doi: 10.1056/NEJM198101083040201
49. Weir M, Zhao H, Han MK, Kanner R, Pirozzi CS, Scholand MB, et al. Eosinophils in chronic obstructive pulmonary disease, the SPIROMICS cohort. Am J Respir Crit Care Med. 2014;189:A5902.
50. Vedel-Krogh S, Nielsen SF, Lange P, Vestbo J, Nordestgaard BG. Blood Eosinophils and Exacerbations in Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study. Am J Respir Crit Care Med. 2016 May 1;193(9):965-74. doi: 10.1164/rccm.201509-1869OC
51. Klion AD. Eosinophilia: a pragmatic approach to diagnosis and treatment. Hematol Am Soc Hematol Educ Program. 2015;2015:92-7. doi: 10.1182/asheducation-2015.1.92
52. Tsiligianni I, Kaplan AG. Are blood eosinophils a prime-time biomarker for COPD management decisions? Int J COPD. 2018;13:1889-91. doi: 10.2147/COPD.S163749
53. Schleich F, Corhay JL, Louis R. Blood eosinophil count to predict bronchial eosinophilic inflammation in COPD. Eur Respir J. 2016;47:1299-303. doi: 10.1183/13993003.01659-2015
54. Soter S, Barta I, Antus B. Predicting sputum eosinophilia in exacerbations of COPD using exhaled nitric oxide. Inflammation. 2013;36(5):1178-85. doi: 10.1007/s10753-013-9653-8
55. Gao J, Zhang M, Zhou L, Yang X, Wu H, Zhang J, Wu F. Correlation between fractional exhaled nitric oxide and sputum eosinophilia in exacerbations of COPD. Int J Chron Obstruct Pulmon Dis. 2017 Apr 27;12:1287-93. doi: 10.2147/COPD.S134998. eCollection 2017.
56. Lams BE, Sousa AR, Rees PJ, Lee TH. Subepithelial immunopathology of the large airways in smokers with and without chronic obstructive pulmonary disease. Eur Respir J. 2000 Mar;15(3):512-6. PMID: 10759445
57. Hastie AT, Martinez FJ, Curtis JL, Doerschuk CM, et al, for SPIROMICS. Sputum or blood eosinophil association with clinical measures of COPD severity in the SPIROMICS cohort. Lancet Respir Med. 2017 Dec;5(12):956-67. Pub. online 2017 Nov 13. doi: 10.1016/S2213-2600(17)30432-0
58. Zanini A, Cherubino F, Zampogna E, Croce S, Pignatti P, Spanevello A. Bronchial hyperresponsiveness, airway inflammation, and reversibility in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:1155-61. Pub. online 2015 Jun 17. doi: 10.2147/COPD.S80992
59. Oshagbemi OA, Franssen FME, Braeken DCW, Henskens Y, Wouters EFM, Maitland-van der Zee AH, Burden AM, de Vries F. Blood eosinophilia, use of inhaled corticosteroids, and risk of COPD exacerbations and mortality. Pharmacoepidemiol Drug Saf. 2018 Nov;27(11):1191-9. doi: 10.1002/pds.4655. Epub 2018 Sep 28.
60. Kerkhof M, Freeman D, Jones R, Chisholm A, Price DB; Respiratory Effectiveness Group. Predicting frequent COPD exacerbations using primary care data. Int J Chron Obstruct Pulmon Dis. 2015;10:2439-50. doi: 10.2147/COPD.S94259. eCollection 2015.
61. Zysman M, Deslee G, Caillaud D, Chanez P, et al. Relationship between blood eosinophils, clinical characteristics, and mortality in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:1819-24. doi: 10.2147/COPD.S129787
62. Duman D, Aksoy E, Agca MC, Kocak ND, et al. The utility of inflammatory markers to predict readmissions and mortality in COPD cases with or without eosinophilia. Int J Chron Obstruct Pulmon Dis. 2015 Nov 11;10:2469-78. doi: 10.2147/COPD.S90330. eCollection 2015.
63. Holland M, Alkhalil M, Chandromouli S, Janjua A, Babores M. Eosinopenia as a marker of mortality and length of stay in patients admitted with exacerbations of chronic obstructive pulmonary disease. Respirology. 2010 Jan;15(1):165-7. doi: 10.1111/j.1440-1843.2009.01651.x. Epub 2009 Nov 30. PMID: 19947999
64. Saltürk C, Karakurt Z, Adiguzel N, Kargin F, et al. Does eosinophilic COPD exacerbation have a better patient outcome than non-eosinophilic in the intensive care unit? Int J Chron Obstruct Pulmon Dis. 2015;10:1837-46. doi: 10.2147/COPD.S88058
65. Couillard S, Larivée P, Courteau J, Vanasse A. Eosinophils in chronic obstructive pulmonary disease exacerbations are associated with increased readmissions. CHEST. 2016. doi: 10.1016/j.chest.2016.10.003
66. Ho J, He W, Chan MTV, Tse G, et al. Eosinophilia and clinical outcome of chronic obstructive pulmonary disease: a meta-analysis. Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD. Sci Rep. 2017;7. doi: 10.1038/s41598-017-13745-x
67. Rahimi-Rada MH, Asgarib B, Hosseinzadehc N, Eishid A. Eosinopenia as a marker of outcome in acute exacerbations of chronic obstructive pulmonary disease. MAEDICA – J Clin Med. 2015;10(1):10-13.
68. Müllerová H, Meeraus W, Galkin DV, Albers FC, Landis SH. Clinical burden of illness among patients with severe eosinophilic COPD. Int J Chron Obstruct Pulmon Dis. 2019 Mar 28;14:741-55. doi: 10.2147/COPD.S194511. eCollection 2019.
69. Bacci E, Cianchetti S, Bartoli M, Dente FL, Di Franco A, Vagaggini B, Paggiaro P. Low sputum eosinophils predict the lack of response to beclomethasone in symptomatic asthmatic patients. Chest. 2006;129(3):565-72. doi: 10.1378/chest.129.3.565
70. Siva R, Green RH, Brightling CE, Shelley M, Hargadon B, McKenna S, Monteiro W, Berry M, Parker D, Wardlaw AJ, Pavord ID. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J. 2007;29(5):906-13. doi: 10.1183/09031936.00146306
71. Siddiqui SH, Guasconi A, Vestbo J, Jones P, Agusti A, Paggiaro P, Wedzicha JA, Singh D. Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015 Aug 15;192(4):523-5. doi: 10.1164/rccm.201502-0235LE
72. Pavord ID, Chanez P, Criner GJ, et al. Mepolizumab for eosinophilic chronic obstructive pulmonary disease. N Engl J Med. 2017 Oct 26;377(17):1613-29. doi: 10.1056/NEJMoa1708208. Epub 2017 Sep 11.
73. Pascoe S, Barnes N, Brusselle G, et al. Blood eosinophil counts and treatment response in COPD: analyses of IMPACT. Eur Respir J. 2018;52:OA2127. doi: 10.1183/13993003.congress-2018.OA2127
74. Barnes NC, Sharma R, Lettis S, Calverley PM. Blood eosinophils as a marker of response to inhaled corticosteroids in COPD. Eur Respir J. 2016 May;47(5):1374-82. doi: 10.1183/13993003.01370-2015. Epub 2016 Feb 25.
75. Suissa S, Dell’Aniello S, Ernst P. Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study. Lancet Respir Med. 2018 Nov;6(11):855-62. doi: 10.1016/S2213-2600(18)30368-0. Epub 2018 Oct 18.
76. Papi A, Kostikas K, Wedzicha JA, Vogelmeier CF, Roche N, Shen S, Banerji D, Fogel R, Patalano F, Chapman KR. Dual bronchodilation response by exacerbation history and eosinophilia in the FLAME study. Am J Respir Crit Care Med. Epub 2017 Nov 3. doi: 10.1164/rccm.201709-1822LE
77. Roche N, Chapman KR, Vogelmeier CF, Herth FJF, Thach C, Fogel R, et al. Blood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment. Data from the FLAME Trial. Am J Respir Crit Care Med. 2017;195(9):1189-97. doi: 10.1164/rccm.201701-0193OC
78. Iqbal A, Barnes NC, Brooks B. Is blood eosinophil count a predictor of response to bronchodilators in COPD? Clin Drug Investig. 2015 Oct;35(10):685-8. doi: 10.1007/s40261-015-0322-6
79. Calverley P, Hallmann C, Metzdorf N, Grnke L, Mueller A, Halpin D. Tiotropium efficacy and exacerbation risk in patients with different blood eosinophil levels. Eur Respir J. 2015;46(Suppl 59):PA4362. doi: 10.1183/13993003.congress-2015.PA4362
80. Dasgupta A, Kjarsgaard M, Capaldi D, Radford K, et al. A pilot randomised clinical trial of mepolizumab in COPD with eosinophilic bronchitis. Eur Respir J. 2017;49:1602486. doi: 10.1183/13993003.02486-2016
81. Lee J, Machin M, Russell KE, Pavlidis S, et al. Corticosteroid modulation of immunoglobulin expression and B-cell function in COPD. FASEB J 2016; 30: 2014–2026. FASEB J. 2016 May;30(5):2014-26. doi: 10.1096/fj.201500135. Epub 2016 Feb 17.
82. Bourbeau J, Christodoulopoulos P, Maltais F, Yamauchi Y, Olivenstein R, Hamid Q. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax. 2007;62:938-43. doi: 10.1136/thx.2006.071068
83. Ballarin A, Bazzan E, Zenteno RH, Turato G, Baraldo S, Zanovello D, Mutti E, Hogg JC, Saetta M, Cosio MG. Mast cell infiltration discriminates between histopathological phenotypes of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012 Aug 1;186(3):233-9. doi: 10.1164/rccm.201112-2142OC. Epub 2012 Jun 7.
84. Criner GJ, Celli BR, Brightling CE, Agusti A, et al, for the GALATHEA and TERRANOVA Study Investigators Benralizumab for the Prevention of COPD Exacerbations. New Engl J Med. Published online May 20, 2019, at NEJM.org. doi: 10.1056/NEJMoa1905248
85. Park HY, Lee H, Koh W-Y, Kim S, Jeong I, Koo H-K, Kim T-H, Kim J, Kim JW, Oh YM, Sin DD, Lim SY, Lee SD; KOLD Study Group. Association of blood eosinophils and plasma periostin with FEV1 response after 3-month inhaled corticosteroid and long-acting beta2-agonist treatment in stable COPD patients. Int J Chron Obstruct Pulmon Dis. 2015 Dec 22;11:23-30. doi: 10.2147/COPD.S94797
________________________________________________
1. [Aisanov ZR, Avdeev SN, Arkhipov VV, Belevskiy AS, Leshchenko IV, Ovcharenko SI, Shmelev EI, Chuchalin AG. National clinical guidelines on diagnosis and treatment of chronic obstructive pulmonary disease: a clinical decision-making algorithm. Russian Pulmonology. 2017;27(1):13-20. (In Russ.)]. doi: 10.18093/0869-0189-2017-27-1-13-20.
2. Fragoso E, André S, Boleo-Tomé JP, Areias V, Munhá J, Cardoso J. Understanding COPD: A vision on phenotypes, comorbidities and treatment approach. GI COPD – Interest Group on Chronic Obstructive Pulmonary Disease. Rev Port Pneumol. 2016 Mar-Apr;22(2):101-11. doi: 10.1016/j.rppnen.2015.12.001. Epub 2016 Jan 27. Review.
3. Saetta M, Di Stefano A, Maestrelli P, Turato G, Ruggieri MP, Roggeri A, Calcagni P, Mapp CE, Ciaccia A, Fabbri LM. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med. 1994;150:1646-52. doi: 10.1164/ajrccm.150.6.7952628
4. Saetta M, Di Stefano A, Maestrelli P, Turato G, Mapp CE, Pieno M, Zanguochi G, Del Prete G, Fabbri LM. Airway eosinophilia and expression of interleukin-5 protein in asthma and in exacerbations of chronic bronchitis. Clin Exp Allergy. 1996;26:766-74. doi: 10.1007/978-3-0348-7939-2_2
5. Pizzichini E, Pizzichini MM, Gibson P, Parameswaran K, Gleich GJ, Berman L, Dolovich J, Hargreave FE. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med. 1998;158(5 Pt 1):1511-7. doi: 10.1164/ajrccm.158.5.9804028
6. Landis S, Suruki R, Bonar K, Hilton E, Compton C. Demographic and Clinical Characteristics of COPD Patients at Different Blood eosinophil levels in the UK Clinical Practice Research Datalink (CPRD). Am J Respir Crit Care Med. 2016;193:A6329. DOI: 10.1080/15412555.2018.1441275
7. Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomized controlled trials. Lancet Respir Med. 2015;3(6):435-42. doi: 10.1016/S2213-2600(15)00106-X. Epub 2015 Apr 12.
8. Singh D, Kolsum U, Brightling CE, Locantore N, Agusti A, Tal-Singer R. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J. 2014 Dec;44(6):1697-700. doi: 10.1183/09031936.00162414. Epub 2014 Oct 16.
9. George L, Brightling CE Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease. Ther Adv Chronic Dis. 2016;7(1):34-51. doi: 10.1177/2040622315609251
10. Joo MJ, Au DH, Fitzgibbon ML, Lee TA. Inhaled corticosteroids and risk of pneumonia in newly diagnosed COPD. Respir Med. 2010 Feb;104(2):246-52. doi: 10.1016/j.rmed.2009.10.002. Epub 2009 Oct 30.
11. Morjaria JB, Rigby A, Morice AH. Inhaled Corticosteroid use and the Risk of Pneumonia and COPD Exacerbations in the UPLIFT Study. Lung. 2017 Jun;195(3):281-8. doi: 10.1007/s00408-017-9990-8. Epub 2017 Mar 3.
12. Yang M, Chen H, Zhang Y, Du Y, Xu Y, Jiang P, Xu Z. Long-term use of inhaled corticosteroids and risk of upper respiratory tract infection in chronic obstructive pulmonary disease: a meta-analysis. Inhal Toxicol. 2017 Apr;29(5):219-26. doi: 10.1080/08958378.2017.1346006. Epub 2017 Jul 17.
13. Di Santostefano RL, Hinds D, Le HV, Barnes NC. Relationship between blood eosinophils and clinical characteristics in a cross-sectional study of a US population-based COPD cohort. Respir Med. 2016 Mar;112:88-96. doi: 10.1016/j.rmed.2016.01.013. Epub 2016 Jan 22.
14. Kolsum U, Damera G, Pham TH, Southworth T, Mason S, Karur P, Newbold P, Singh D. Pulmonary inflammation in patients with chronic obstructive pulmonary disease with higher blood eosinophil counts. J Allergy Clin Immunol. 2017 Oct;140(4):1181-4.e7. doi: 10.1016/j.jaci. 2017.04.027. Epub 2017 May.
15. Hasegawa K, Camargo CA. 2016 Prevalence of blood eosinophilia in hospitalized patients with acute exacerbation of COPD. Respirology. 2016;21:761-4. doi: 10.1111/resp.12724
16. Bafadhel M, Saha S, Siva R, McCormick M, Monteiro W, Rugman P, Dodson P, Pavord ID, Newbold P, Brightling CE. Sputum IL-5 concentration is associated with a sputum eosinophilia and attenuated by corticosteroid therapy in COPD. Respiration. 2009;78:256-62. doi: 10.1159/000221902
17. Ying S, O'Connor B, Ratoff J, Meng Q, Fang C, Cousins D, Zhang G, Gu S, Gao Z, Shamji B, Edwards MJ, Lee TH, Corrigan CJ. Expression and cellular provenance of thymic stromal lymphopoietin and chemokines in patients with severe asthma and chronic obstructive pulmonary disease. J Immunol. 2008;181:2790-8. doi: 10.4049/jimmunol.181.4.2790
18. Saha S, Doe C, Mistry V, Siddiqui S, Parker D, Sleeman M, Cohen ES, Brightling CE. Granulocyte-macrophage colony-stimulating factor expression in induced sputum and bronchial mucosa in asthma and COPD. Thorax. 2009 Aug;64(8):671-6. doi: 10.1136/thx.2008.108290. Epub 2009 Feb 12.
19. Tworek D, Antczak A. Eosinophilic COPD – a distinct phenotype of the disease. Adv Respir Med. 2017;85(5):271-6. doi: 10.5603/ARM.a2017.0045
20. D'Armiento JM, Scharf SM, Roth MD, Connett JE, Ghio A, et al. Eosinophil and T cell markers predict functional decline in COPD patients. Respir Res. 2009 Nov 19;10:113. doi: 10.1186/1465-9921-10-113
21. Ponath PD, Qin S, Ringler DJ, Clark-Lewis I, et al. Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. J Clin Invest. 1996 Feb 1;97(3):604-12. doi: 10.1172/JCI118456
22. Brusselle G, Pavord ID, Landis S, Pascoe S, Lettis S, Morjaria N, Barnes N, Hilton E. Blood eosinophil levels as a biomarker in COPD. Respir Med. 2017. doi: 10.1016/ j.rmed.2018.03.016
23. Barnes PJ. Inflammatory Endotypes in COPD. Allergy. 2019 Mar 4. doi: 10.1111/all.13760
24. Christenson SA, Steiling K, van den Berge M, Hijazi K, Hiemstra PS, Postma DS, Lenburg ME, Spira A, Woodruff PG. Asthma-COPD overlap. Clinical relevance of genomic signatures of type 2 inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;191(7):758-66. doi: 10.1164/rccm.201408-1458OC
25. Brightling CE, Bleecker ER, Panettieri RA Jr, Bafadhel M, She D, Ward CK, Xu X, Birrell C, van der Merwe R. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med. 2014 Nov;2(11):891-901. doi: 10.1016/S2213-2600(14)70187-0. Epub 2014 Sep 7.
26. Eltboli O, Bafadhel M, Hollins F, Wright A, Hargadon B, Kulkarni N, Brightling C. COPD exacerbation severity and frequency is associated with impaired macrophage efferocytosis of eosinophils. BMC Pulm Med. 2014 Jul 9;14:112. doi: 10.1186/1471-2466-14-112
27. Akiyama M, Yasuoka H, Yoshimoto K, Takeuchi T. CC-chemokine ligand 18 is a useful biomarker associated with disease activity in IgG4-related disease. Ann Rheum Dis. 2018 Sep;77(9):1386-7. doi: 10.1136/annrheumdis-2017-212110. Epub 2017 Oct 13.
28. Laucho-Contreras ME, Polverino F, Tesfaigzi Y, Pilon A, Celli BR, Owen CA. Club Cell Protein 16 (CC16) Augmentation: A Potential Disease-modifying Approach for Chronic Obstructive Pulmonary Disease (COPD). Expert Opin Ther Targets. 2016 Jul;20(7):869-83. doi: 10.1517/14728222.2016.1139084. Epub 2016 Feb 11.
29. Tashkin DP, Wechsler ME. Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2018 Jan 17;13:335-49. doi: 10.2147/COPD.S152291. eCollection 2018.
30. Bafadhel M, McKenna S, Terry S, Mistry V, et al. Acute exacerbations of chronic obstructive pulmonary disease: Identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184:662-71. doi: 10.1164/rccm.201104-0597OC
31. McDonald VM, Higgins I, Wood LG, Gibson PG. Multidimensional assessment and tailored interventions for COPD: respiratory utopia or common sense? Thorax. 2013;68(7):691-4. doi: 10.1136/thoraxjnl-2012-202646. Epub 2013 Mar 16.
32. Leigh R, Pizzichini MM, Morris MM, Maltais F, Hargreave FE, Pizzichini E. Stable COPD: predicting benefits from high-dose inhaled corticosteroid treatment. Eur Respir J. 2006;27(5):964-71. doi: 10.1183/09031936.06.00072105
33. Cheng SL, Lin CH. Effectiveness using higher inhaled corticosteroid dosage in patients with COPD by different blood eosinophilic counts. Int J Chron Obstruct Pulmon Dis. 2016 Sep 21;11:2341-8. eCollection 2016. doi: 10.2147/COPD.S115132
34. Baines KJ, Pavord ID, Gibson PG. The role of biomarkers in the management of airways disease. Int J Tuberc Lung Dis. 2014 Nov;18(11):1264-8. doi: 10.5588/ijtld.14.0226
35. Simpson JL, Bafadhel M. Alternatives to induced sputum for identifying inflammatory subtypes of asthma. Respirology. 2017 May;22(4):624-5. doi: 10.1111/resp.13036. Epub 2017 Mar 29. PMID: 28370689
36. Hastie AT, Alexis NE, Doerschuk C, Hansel NN, Christenson S, Putcha N, et al. Blood eosinophils poorly correlate with sputum eosinophils, and have few associations with spirometry, clinical and quantitated computed tomography measures compared to sputum eosinophils in the SPIROMICS cohort. Am J Respir Crit Care Med. 2016;193:A6168.
37. Kolsum U, Ravi A, Hitchen P, Maddi S, Southworth T, Singh D. Clinical characteristics of eosinophilic COPD versus COPD patients with a history of asthma. Respir Res. 2017;18:73. Pub. online 2017 Apr 26. doi: 10.1186/s12931-017-0559-0
38. Negewo NA, McDonald VM, Baines KJ, Wark PA, Simpson JL, Jones PW, Gibson PG. Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD. Int J Chron Obstruct Pulmon Dis. 2016 Jul 1;11:1495-504. doi: 10.2147/COPD.S100338. eCollection 2016.
39. Turato G, Semenzato U, Bazzan E, Biondini D, Tinè M, Torrecilla N, Forner M, Marin JM, Cosio MG, Saetta M. Blood Eosinophilia Neither Reflects Tissue Eosinophils nor Worsens Clinical Outcomes in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2018 May 1;197(9):1216-9. doi: 10.1164/rccm.201708-1684LE
40. Yilmaz I, Turk M. What Should Be the Cutoff Value of Blood Eosinophilia as a Predictor of Inhaled Corticosteroid Responsiveness in Patients with Chronic Obstructive Pulmonary Disease? Am J Respir Crit Care Med. 2017 Nov 1;196(9):1229-30. doi: 10.1164/rccm.201705-0892LE
41. Wedzicha JA. Eosinophils as biomarkers of chronic obstructive pulmonary disease exacerbation risk: maybe just for some? Am J Respir Crit Care Med. 2016;193:937-8. doi: 10.1164/rccm.201601-0015ED
42. Shin SH, Park HY, Kang D, Cho J, Kwon SO, Park JH, Lee JS, Oh YM, Sin DD, Kim WJ, Lee SD and KOLD Study Group. Serial blood eosinophils and clinical outcome in patients with chronic obstructive pulmonary disease. Respir Res. 2018 Jul 13;19(1):134. doi: 10.1186/s12931-018-0840-x
43. Calverley PMA, Tetzlaff K, Vogelmeier C, Fabbri LM, Magnussen H, Wouters EFM, Mezzanotte W, Disse B, Finnigan H, Asijee G, Hallmann C, Watz H. Eosinophilia, frequent exacerbations, and steroid response in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017 Nov 1;196(9):1219-21. doi: 10.1164/rccm.201612-2525LE
44. Casanova C, Celli BR, de-Torres JP, Martínez-Gonzalez C, et al. Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD. Eur Respir J. 2017;50(5). pii: 1701162. doi: 10.1183/13993003.01162-2017
45. Szefler SJ, Wenzel S, Brown R, Erzurum SC, et al. Asthma outcomes: biomarkers. J Allergy Clin Immunol. 2012 Mar;129(3 Suppl):S9-23. doi: 10.1016/j.jaci.2011.12.979
46. Oshagbemi OA, Burden AM, Braeken DCW, Henskens Y, et al. Stability of blood eosinophils in patients with chronic obstructive pulmonary disease and in control subjects, and the impact of sex, age, smoking, and baseline counts. Am J Respir Crit Care Med. 2017;195(10):1402-4. doi: 10.1164/rccm.201701-0009LE
47. Sennels HP, Jørgensen HL, Hansen AL, Goetze JP, Fahrenkrug J. Diurnal variation of hematology parameters in healthy young males: the Bispebjerg study of diurnal variations. Scand J Clin Lab Invest. 2011;71(7):532-41. doi: 10.3109/00365513.2011.602422
48. Shekelle RB, Shryock AM, Paul O, Lepper M, Stamler J, Liu S, et al. Diet, serum cholesterol, and death from coronary heart disease. The Western Electric study. N Engl J Med. 1981;304(2):65-70. doi: 10.1056/NEJM198101083040201
49. Weir M, Zhao H, Han MK, Kanner R, Pirozzi CS, Scholand MB, et al. Eosinophils in chronic obstructive pulmonary disease, the SPIROMICS cohort. Am J Respir Crit Care Med. 2014;189:A5902.
50. Vedel-Krogh S, Nielsen SF, Lange P, Vestbo J, Nordestgaard BG. Blood Eosinophils and Exacerbations in Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study. Am J Respir Crit Care Med. 2016 May 1;193(9):965-74. doi: 10.1164/rccm.201509-1869OC
51. Klion AD. Eosinophilia: a pragmatic approach to diagnosis and treatment. Hematol Am Soc Hematol Educ Program. 2015;2015:92-7. doi: 10.1182/asheducation-2015.1.92
52. Tsiligianni I, Kaplan AG. Are blood eosinophils a prime-time biomarker for COPD management decisions? Int J COPD. 2018;13:1889-91. doi: 10.2147/COPD.S163749
53. Schleich F, Corhay JL, Louis R. Blood eosinophil count to predict bronchial eosinophilic inflammation in COPD. Eur Respir J. 2016;47:1299-303. doi: 10.1183/13993003.01659-2015
54. Soter S, Barta I, Antus B. Predicting sputum eosinophilia in exacerbations of COPD using exhaled nitric oxide. Inflammation. 2013;36(5):1178-85. doi: 10.1007/s10753-013-9653-8
55. Gao J, Zhang M, Zhou L, Yang X, Wu H, Zhang J, Wu F. Correlation between fractional exhaled nitric oxide and sputum eosinophilia in exacerbations of COPD. Int J Chron Obstruct Pulmon Dis. 2017 Apr 27;12:1287-93. doi: 10.2147/COPD.S134998. eCollection 2017.
56. Lams BE, Sousa AR, Rees PJ, Lee TH. Subepithelial immunopathology of the large airways in smokers with and without chronic obstructive pulmonary disease. Eur Respir J. 2000 Mar;15(3):512-6. PMID: 10759445
57. Hastie AT, Martinez FJ, Curtis JL, Doerschuk CM, et al, for SPIROMICS. Sputum or blood eosinophil association with clinical measures of COPD severity in the SPIROMICS cohort. Lancet Respir Med. 2017 Dec;5(12):956-67. Pub. online 2017 Nov 13. doi: 10.1016/S2213-2600(17)30432-0
58. Zanini A, Cherubino F, Zampogna E, Croce S, Pignatti P, Spanevello A. Bronchial hyperresponsiveness, airway inflammation, and reversibility in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:1155-61. Pub. online 2015 Jun 17. doi: 10.2147/COPD.S80992
59. Oshagbemi OA, Franssen FME, Braeken DCW, Henskens Y, Wouters EFM, Maitland-van der Zee AH, Burden AM, de Vries F. Blood eosinophilia, use of inhaled corticosteroids, and risk of COPD exacerbations and mortality. Pharmacoepidemiol Drug Saf. 2018 Nov;27(11):1191-9. doi: 10.1002/pds.4655. Epub 2018 Sep 28.
60. Kerkhof M, Freeman D, Jones R, Chisholm A, Price DB; Respiratory Effectiveness Group. Predicting frequent COPD exacerbations using primary care data. Int J Chron Obstruct Pulmon Dis. 2015;10:2439-50. doi: 10.2147/COPD.S94259. eCollection 2015.
61. Zysman M, Deslee G, Caillaud D, Chanez P, et al. Relationship between blood eosinophils, clinical characteristics, and mortality in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:1819-24. doi: 10.2147/COPD.S129787
62. Duman D, Aksoy E, Agca MC, Kocak ND, et al. The utility of inflammatory markers to predict readmissions and mortality in COPD cases with or without eosinophilia. Int J Chron Obstruct Pulmon Dis. 2015 Nov 11;10:2469-78. doi: 10.2147/COPD.S90330. eCollection 2015.
63. Holland M, Alkhalil M, Chandromouli S, Janjua A, Babores M. Eosinopenia as a marker of mortality and length of stay in patients admitted with exacerbations of chronic obstructive pulmonary disease. Respirology. 2010 Jan;15(1):165-7. doi: 10.1111/j.1440-1843.2009.01651.x. Epub 2009 Nov 30. PMID: 19947999
64. Saltürk C, Karakurt Z, Adiguzel N, Kargin F, et al. Does eosinophilic COPD exacerbation have a better patient outcome than non-eosinophilic in the intensive care unit? Int J Chron Obstruct Pulmon Dis. 2015;10:1837-46. doi: 10.2147/COPD.S88058
65. Couillard S, Larivée P, Courteau J, Vanasse A. Eosinophils in chronic obstructive pulmonary disease exacerbations are associated with increased readmissions. CHEST. 2016. doi: 10.1016/j.chest.2016.10.003
66. Ho J, He W, Chan MTV, Tse G, et al. Eosinophilia and clinical outcome of chronic obstructive pulmonary disease: a meta-analysis. Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD. Sci Rep. 2017;7. doi: 10.1038/s41598-017-13745-x
67. Rahimi-Rada MH, Asgarib B, Hosseinzadehc N, Eishid A. Eosinopenia as a marker of outcome in acute exacerbations of chronic obstructive pulmonary disease. MAEDICA – J Clin Med. 2015;10(1):10-13.
68. Müllerová H, Meeraus W, Galkin DV, Albers FC, Landis SH. Clinical burden of illness among patients with severe eosinophilic COPD. Int J Chron Obstruct Pulmon Dis. 2019 Mar 28;14:741-55. doi: 10.2147/COPD.S194511. eCollection 2019.
69. Bacci E, Cianchetti S, Bartoli M, Dente FL, Di Franco A, Vagaggini B, Paggiaro P. Low sputum eosinophils predict the lack of response to beclomethasone in symptomatic asthmatic patients. Chest. 2006;129(3):565-72. doi: 10.1378/chest.129.3.565
70. Siva R, Green RH, Brightling CE, Shelley M, Hargadon B, McKenna S, Monteiro W, Berry M, Parker D, Wardlaw AJ, Pavord ID. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J. 2007;29(5):906-13. doi: 10.1183/09031936.00146306
71. Siddiqui SH, Guasconi A, Vestbo J, Jones P, Agusti A, Paggiaro P, Wedzicha JA, Singh D. Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015 Aug 15;192(4):523-5. doi: 10.1164/rccm.201502-0235LE
72. Pavord ID, Chanez P, Criner GJ, et al. Mepolizumab for eosinophilic chronic obstructive pulmonary disease. N Engl J Med. 2017 Oct 26;377(17):1613-29. doi: 10.1056/NEJMoa1708208. Epub 2017 Sep 11.
73. Pascoe S, Barnes N, Brusselle G, et al. Blood eosinophil counts and treatment response in COPD: analyses of IMPACT. Eur Respir J. 2018;52:OA2127. doi: 10.1183/13993003.congress-2018.OA2127
74. Barnes NC, Sharma R, Lettis S, Calverley PM. Blood eosinophils as a marker of response to inhaled corticosteroids in COPD. Eur Respir J. 2016 May;47(5):1374-82. doi: 10.1183/13993003.01370-2015. Epub 2016 Feb 25.
75. Suissa S, Dell’Aniello S, Ernst P. Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study. Lancet Respir Med. 2018 Nov;6(11):855-62. doi: 10.1016/S2213-2600(18)30368-0. Epub 2018 Oct 18.
76. Papi A, Kostikas K, Wedzicha JA, Vogelmeier CF, Roche N, Shen S, Banerji D, Fogel R, Patalano F, Chapman KR. Dual bronchodilation response by exacerbation history and eosinophilia in the FLAME study. Am J Respir Crit Care Med. Epub 2017 Nov 3. doi: 10.1164/rccm.201709-1822LE
77. Roche N, Chapman KR, Vogelmeier CF, Herth FJF, Thach C, Fogel R, et al. Blood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment. Data from the FLAME Trial. Am J Respir Crit Care Med. 2017;195(9):1189-97. doi: 10.1164/rccm.201701-0193OC
78. Iqbal A, Barnes NC, Brooks B. Is blood eosinophil count a predictor of response to bronchodilators in COPD? Clin Drug Investig. 2015 Oct;35(10):685-8. doi: 10.1007/s40261-015-0322-6
79. Calverley P, Hallmann C, Metzdorf N, Grnke L, Mueller A, Halpin D. Tiotropium efficacy and exacerbation risk in patients with different blood eosinophil levels. Eur Respir J. 2015;46(Suppl 59):PA4362. doi: 10.1183/13993003.congress-2015.PA4362
80. Dasgupta A, Kjarsgaard M, Capaldi D, Radford K, et al. A pilot randomised clinical trial of mepolizumab in COPD with eosinophilic bronchitis. Eur Respir J. 2017;49:1602486. doi: 10.1183/13993003.02486-2016
81. Lee J, Machin M, Russell KE, Pavlidis S, et al. Corticosteroid modulation of immunoglobulin expression and B-cell function in COPD. FASEB J 2016; 30: 2014–2026. FASEB J. 2016 May;30(5):2014-26. doi: 10.1096/fj.201500135. Epub 2016 Feb 17.
82. Bourbeau J, Christodoulopoulos P, Maltais F, Yamauchi Y, Olivenstein R, Hamid Q. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax. 2007;62:938-43. doi: 10.1136/thx.2006.071068
83. Ballarin A, Bazzan E, Zenteno RH, Turato G, Baraldo S, Zanovello D, Mutti E, Hogg JC, Saetta M, Cosio MG. Mast cell infiltration discriminates between histopathological phenotypes of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012 Aug 1;186(3):233-9. doi: 10.1164/rccm.201112-2142OC. Epub 2012 Jun 7.
84. Criner GJ, Celli BR, Brightling CE, Agusti A, et al, for the GALATHEA and TERRANOVA Study Investigators Benralizumab for the Prevention of COPD Exacerbations. New Engl J Med. Published online May 20, 2019, at NEJM.org. doi: 10.1056/NEJMoa1905248
85. Park HY, Lee H, Koh W-Y, Kim S, Jeong I, Koo H-K, Kim T-H, Kim J, Kim JW, Oh YM, Sin DD, Lim SY, Lee SD; KOLD Study Group. Association of blood eosinophils and plasma periostin with FEV1 response after 3-month inhaled corticosteroid and long-acting beta2-agonist treatment in stable COPD patients. Int J Chron Obstruct Pulmon Dis. 2015 Dec 22;11:23-30. doi: 10.2147/COPD.S94797
1 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia;
2 Pulmonology Scientific Research Institute, Moscow, Russia
________________________________________________
S.N. Avdeev 1,2, N.V. Trushenko 1,2, Z.M. Merzhoeva 1,2, M.S. Ivanova 1, E.V. Kusraeva 1
1 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia;
2 Pulmonology Scientific Research Institute, Moscow, Russia